Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
62.22
-0.41 (-0.65%)
At close: Feb 27, 2026, 4:00 PM EST
62.00
-0.22 (-0.35%)
After-hours: Feb 27, 2026, 7:28 PM EST
Cytokinetics Employees
Cytokinetics had 498 employees as of December 31, 2024. The number of employees increased by 75 or 17.73% compared to the previous year.
Employees
498
Change (1Y)
75
Growth (1Y)
17.73%
Revenue / Employee
$176,785
Profits / Employee
-$1,576,215
Market Cap
7.66B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| Axsome Therapeutics | 925 |
| Arrowhead Pharmaceuticals | 711 |
| Vaxcyte | 507 |
| Halozyme Therapeutics | 423 |
| Krystal Biotech | 295 |
| Cogent Biosciences | 258 |
| Kymera Therapeutics | 225 |
CYTK News
- 3 days ago - Cytokinetics, Incorporated (CYTK) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 11 days ago - Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy - GlobeNewsWire
- 16 days ago - Cytokinetics to Announce Fourth Quarter Results on February 24, 2026 - GlobeNewsWire
- 19 days ago - Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program - GlobeNewsWire
- 4 weeks ago - Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms - GlobeNewsWire
- 5 weeks ago - The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors - Business Wire
- 5 weeks ago - Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire